Dr. Vinay Prasad Resumes Leadership Role at FDA Amid Controversy and Political Pressure

Dr. Vinay Prasad Returns to FDA Amid Controversy and Political Pressure

(CNN) — Dr. Vinay Prasad, a prominent and polarizing figure in the realm of public health, has resumed his leadership role at the U.S. Food and Drug Administration (FDA) just weeks after resigning under intense scrutiny from the White House and right-wing activist Laura Loomer.

In a statement released Saturday, Health and Human Services spokesperson Andrew Nixon confirmed, “At the FDA’s request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research.” However, Nixon did not clarify whether Prasad would also reclaim his position as the FDA’s chief medical and scientific officer.

Prasad, a hematologist oncologist known for his outspoken critiques of the FDA’s drug approval processes and pandemic response, initially stepped down in late July. He cited a desire to avoid becoming a distraction to the agency’s important work and expressed a wish to return to California to spend more time with his family.

His resignation came amid mounting pressure from the White House and a barrage of criticism from Loomer, who has garnered significant attention for her vocal opposition to Prasad. Loomer labeled him a “progressive leftist saboteur” on her social media platforms, accusing him of undermining President Trump’s FDA. Her campaign against Prasad included references to his past social media posts and podcast appearances, where he expressed views that aligned with liberal politicians.

The backlash against Prasad was not limited to Loomer. Former U.S. Senator Rick Santorum and others joined the fray, with Santorum accusing Prasad of “destroying @POTUS legacy for helping patients.” A Wall Street Journal opinion piece further fueled the fire, branding him a “Bernie Sanders acolyte in MAHA drag.”

Prasad’s tenure at the FDA has been marked by controversy, particularly regarding his decisions on COVID-19 vaccine approvals. Internal memos revealed that he had overridden FDA scientists on recommendations for new vaccine versions, leading to criticism from former officials and vaccine experts alike. The FDA ultimately approved the vaccines for older and immunocompromised individuals but did not recommend them for younger Americans without underlying health conditions.

In response to Prasad’s reinstatement, Loomer condemned the decision as “egregious” and vowed to intensify her scrutiny of officials within the Department of Health and Human Services and the FDA in the coming weeks.

As Dr. Prasad returns to a pivotal role in the FDA, the agency faces renewed scrutiny and division, raising questions about the intersection of politics and public health in the ongoing battle against COVID-19 and beyond.